All entries for: Genentech

June 12, 2026

Genentech

Layoffs

South San Francisco, CA
10,000+ employees

Genentech has made changes to its research and early development group (gRED) that include parting ways with a high-profile executive who had been with the company since 1997. The South San Franciso–based biotech confirmed to BioSpace the “targeted adjustments” and departure of Vishva Dixit, who most recently served as vice president and senior fellow, physiological chemistry, research biology.

The restructuring is intended to ensure the Roche subsidiary’s capabilities and investments align with its core therapeutic areas, advance its portfolio and deliver transformative medicines to patients faster, according to Genentech. A spokesperson declined to share specific information about the layoffs, including how many employees were affected.

Endpoints News reported that Genentech is closing infectious disease and physiological chemistry units while downsizing other teams. Also, in addition to Dixit, other key departures include Todd McDevitt, vice president and head of cell therapy, and Man-Wah Tan, a vice president and senior fellow of infectious diseases, the media outlet reported.

Disease Area: Dermatology, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
February 9, 2026

Genentech

Layoffs

South San Francisco, CA
10,000+ employees

A California WARN notice revealed that 141 employees were laid off across Genentech’s operations, with the terminations taking effect in August 2025. A company spokesperson attributed the delayed posting to a system glitch.

Disease Area: Cardiology, Hematology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
October 30, 2025

Genentech

Layoffs

South San Francisco, CA
10,000+ employees

Genentech is laying off employees at its South San Francisco headquarters. According to a Worker Adjustment and Retraining Notification (WARN) Act notice, 118 staffers will lose their jobs effective Nov. 28.

Disease Area: Cardiology, Hematology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 25, 2025

Genentech

Layoffs

South San Francisco, CA
10,000+ employees

Genentech is letting go of 87 employees at its South San Francisco headquarters, the second round of layoffs at the Roche subsidiary this year.

Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
June 12, 2025

Genentech

Layoffs

South San Francisco, CA
10,000+ employees

Laying off 143 workers at their headquarters in South San Francisco.

Disease Area: Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
August 10, 2023

Genentech

Negative Outlook

South San Francisco, CA
10,000+ employees

“Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Speaking about an experimental therapy in the works that could treat ovarian cancer, breast cancer, and prostate cancer, he said, “Normally, we would develop it in a fast market approach for ovarian cancer. That’s the shortest path to patients … but that is a much smaller indication than prostate cancer, which would take three years longer.”

“So the dilemma we’re facing right now is, do we go with the initial indication being prostate cancer and then hold off on the development and the approval [for] ovarian [cancer] because the clock will be started with prostate?””

Disease Area: Oncology
Drug Type: Small Molecule
Scroll to Top